84 results on '"Diaz-Rubio, E."'
Search Results
2. Hyperprogression as a distinct outcome after immunotherapy
3. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
4. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database
5. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review
6. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials
7. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
8. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours
9. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer
10. Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients
11. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study)
12. Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients
13. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy
14. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
15. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008
16. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study
17. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables
18. Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer
19. What have we learned and where are we going in the treatment of colorectal and gastric cancer?
20. Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy
21. Capecitabine (Xeloda®) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors
22. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001)
23. 418P Upfront primary tumour resection (UPTR) and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
24. P-99 Circulating RNA detection, circulating tumor cells count, and molecular tumor profiling in a cohort of untreated metastatic colorectal cancer: A prospective multicenter ancillary study to the randomized VISNÚ trials
25. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain
26. Paclitaxel plus vinorelbine: An active regimen in metastatic breast cancer patients with prior anthracycline exposure
27. 1819P - Clinical practice evaluation of opioids induced constipation management in cancer patients: The EIO-Praxis project
28. Colorectal cancer in 2003: state of the art and new developments
29. 1710P - Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project
30. 1709P - Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study
31. 1586P - The quality oncology practice initiative program: Experience in Spain
32. 550P - Evaluation of the sensitivity of RAS mutation detection of the Idylla platform in comparison to the OncoBEAM RAS CRC assay
33. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010
34. 573P - microRNA(miR) subtypes correlates with colorectal cancer(CRC) molecular subtypes: Validation of miR-30b interaction with genes up-regulated in the high-stroma subtype
35. 583P - Impact of tumor location on the efficacy of first-line anti-EGFR monoclonal antibody plus chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC): Retrospective analyses of the randomized MACRO-2 and PLANET trials from TTD Group
36. 539P - Circulating tumor cells (CTCs), molecular alterations and their correlation with characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated in the Spanish TTD VISNÚ Program
37. 492P - Benefits of upfront primary tumour resection (UPTR) according to sidedness in mCRC: Retrospective analyses of TTD MACRO-2 and PLANET randomised trials
38. 1587P - How do Spanish medical oncologists manage breakthrough pain? A national study
39. 129P - First prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis
40. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007
41. 2122 Treatment outcomes according to extended RAS mutation testing in a phase II study of first-line mFOLFOX plus cetuximab followed by cetuximab in monotherapy as maintenance therapy or mFOLFOX plus cetuximab in patients with metastatic colorectal cancer: The MACRO-2 trial
42. 2033 Stage III colorectal cancer (CRC) in Spain: A retrospective analysis from 35 centres
43. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006
44. 1007P - Cetuximab and Concurrent Radiation (Ctx-Rt) for Squamous Cell Carcinoma of the Head and Neck (Scchn) in Elderly and Multi-Morbid Patients
45. 567P - Role of Circulating Tumor Cells (Ctc) in Stage III Colorectal Cancer (Crc)
46. 555P - Association Between Colon Cancer Molecular Subtypes Obtained By Expression Profiling and By Microrna (Mir) Profiling
47. 944: Role of BRCA2 in the susceptibility to familial colorectal cancer type X
48. 1342 - Erlotinib (ERL) versus Pemetrexed (MTA) as Second-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer (NSNSCLC): Efficacy and Safety Data
49. 537P - Differences in Kras and Braf Mutation Prevalence in Metastatic Colorectal Carcinoma Using High-Sensitivity Taqmelt vs Arms-Scorpion Pcr Assays
50. 6004 ORAL Role of Baseline Circulating Tumour Cells and KRas Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemotherapy Plus Bevacizumab: a TTD Spanish Group Cooperative Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.